Baxter International (BAX) Research & Development (2009 - 2026)

Baxter International (BAX) has 18 years of Research & Development data on file, last reported at $139.0 million in Q1 2026.

• Research & Development for Q1 2026 came in at $139.0 million, down 0.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $478.0 million (down 5.35% YoY), and the FY2025 annual result was $518.0 million, down 12.2% from the prior year.
• Research & Development eased to $139.0 million in Q1 2026 per BAX's latest filing, from $140.0 million in the prior quarter.
• Over five years, Research & Development peaked at $176.0 million in Q1 2024 and troughed at $2.0 million in Q4 2022.
• A 5-year average of $129.5 million and a median of $150.0 million in 2022 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2023: Research & Development plunged 98.52% in 2022, then jumped 1050.0% in 2023.
• A 5-year view of Research & Development shows it stood at $2.0 million in 2022, then jumped by 1050.0% to $23.0 million in 2023, then jumped by 665.22% to $176.0 million in 2024, then declined by 20.45% to $140.0 million in 2025, then decreased by 0.71% to $139.0 million in 2026.
• Business Quant data shows BAX's Research & Development at $139.0 million in Q1 2026, $140.0 million in Q1 2025, and $176.0 million in Q1 2024.